Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin vs Atorvastatin in STEMI
NCT05895123Phase 2Completed
- Sponsor
- Damanhour University
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in ST-segment elevation myocardial infarction (STEMI) comparing Rosuvastatin group with Atorvastatin group (2 arms). Primary endpoint: Evaluation of the effect on ventricular remodeling at 3 months. Started Nov 2021; status: completed.
02
Drugs
rosuvastatinatorvastatin
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05895123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895123.